Clinical Trials Directory

Trials / Completed

CompletedNCT03187821

Comparison of Superior vs Nasal/Temporal Laser Peripheral Iridotomy in Primary Angle Closure

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
1,000 (actual)
Sponsor
Venkatesh Rengaraj · Academic / Other
Sex
All
Age
30 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine if location of laser peripheral iridotomy (LPI) that is the standard of care treatment for angle closure glaucoma is related to changes in post-operative intraocular pressure (IOP), endothelial cell count,anterior chamber angle morphology and onset of new visual disturbances.

Detailed description

Study hypothesis: Location of laser peripheral iridotomy affects occurrence of post-operative dysphotopsia symptoms, intraocular pressure, anterior chamber angle morphology and corneal endothelial cell count Study design: Multicenter randomized, prospective, single masked trial Trial setting: Hospitals Trial type: Treatment Interventions: South Indian subjects aged 30 years or greater, with primary angle closure suspect (PACS) or primary angle closure/ primary angle closure glaucoma(PAC/PACG) will be randomized to either bilateral superior or nasal/temporal laser peripheral iridotomy. Subjects will undergo noninvasive testing and imaging studies to measure IOP, anterior chamber angle morphology and endothelial cell count and asked to answer a questionnaire at baseline and again at 2 weeks and 6 months after treatment Primary outcome measures: Occurrence of new self-reported general eye or dysphotopsia symptoms. Secondary outcome measures: intraocular pressure, anterior chamber and anterior chamber angle morphology, endothelial cell count.

Conditions

Interventions

TypeNameDescription
PROCEDURELaser peripheral iridotomylocation of laser peripheral iridotomy

Timeline

Start date
2012-09-01
Primary completion
2014-01-01
Completion
2015-01-01
First posted
2017-06-15
Last updated
2017-06-15

Source: ClinicalTrials.gov record NCT03187821. Inclusion in this directory is not an endorsement.